GoodRx (NASDAQ:GDRX) Major Shareholder Sells $437,819.12 in Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $3.44, for a total value of $437,819.12. Following the completion of the transaction, the insider directly owned 643,466 shares of the company’s stock, valued at approximately $2,213,523.04. This trade represents a 16.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The shares were sold at an average price of $3.46, for a total value of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The stock was sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Stock Up 5.2%

NASDAQ:GDRX traded up $0.18 during trading hours on Wednesday, reaching $3.65. The company had a trading volume of 3,534,816 shares, compared to its average volume of 1,909,305. GoodRx Holdings, Inc. has a twelve month low of $1.77 and a twelve month high of $5.81. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.74. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a P/E/G ratio of 1.73 and a beta of 1.60. The business’s 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $2.66.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.09 earnings per share. On average, equities analysts expect that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on GDRX. Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. UBS Group upped their target price on GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Wall Street Zen upgraded GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Citigroup lifted their price target on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a research note on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, GoodRx has an average rating of “Hold” and a consensus target price of $4.23.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Lazard Asset Management LLC grew its holdings in GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after buying an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP lifted its stake in GoodRx by 7.7% during the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after acquiring an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its stake in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after acquiring an additional 6,869 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP purchased a new position in GoodRx during the 3rd quarter worth $33,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.